Literature DB >> 20604639

Oral lichen planus: update on etiopathogenesis, diagnosis and treatment.

Vito Crincoli1, Maria Beatrice Di Bisceglie, Michele Scivetti, Alberta Lucchese, Simona Tecco, Felice Festa.   

Abstract

Lichen planus is an inflammatory mucocutaneous disorder. Skin, oral and genital mucosal surfaces, scalp, and nails can be affected. Its development is chronic, with a possible malignant degeneration. Spontaneous remission is rare. Although the etiology of oral lichen planus is still unclear, there is evidence that it is a complex immunologic disease mediated by cytotoxic cells directed against basilar keratinocytes and resulting in vacuolar degeneration and lysis of basal cells. In long-standing, atrophic and erosive forms, the treatment is usually aimed at relieving pain and may include immunosuppressive agents, especially corticosteroid, topical cyclosporin, or tacrolimus, topical and systemic retinoids. However, the use of these drugs may be accompanied by several side effects. For this reason clinicians, currently, have focused their attention to new biological agents which provide selective immunological results with less side effects than generic immunosupressants.

Entities:  

Mesh:

Year:  2010        PMID: 20604639     DOI: 10.3109/08923973.2010.498014

Source DB:  PubMed          Journal:  Immunopharmacol Immunotoxicol        ISSN: 0892-3973            Impact factor:   2.730


  19 in total

1.  Oral lichen planus.

Authors:  Eric T Stoopler; Thomas P Sollecito
Journal:  CMAJ       Date:  2012-04-02       Impact factor: 8.262

Review 2.  Oral lichenoid lesions: distinguishing the benign from the deadly.

Authors:  Susan Müller
Journal:  Mod Pathol       Date:  2017-01       Impact factor: 7.842

3.  The Expression of CXCL10/CXCR3 and Effect of the Axis on the Function of T Lymphocyte Involved in Oral Lichen Planus.

Authors:  Jiaxiang Fang; Chen Wang; Chen Shen; Jing Shan; Xuewei Wang; Lin Liu; Yuan Fan
Journal:  Inflammation       Date:  2019-06       Impact factor: 4.092

4.  Inflammatory cells of immunosuppressive phenotypes in oral lichen planus have a proinflammatory pattern of expression and are associated with clinical parameters.

Authors:  Marilena Vered; Eran Fürth; Yifat Shalev; Dan Dayan
Journal:  Clin Oral Investig       Date:  2012-08-15       Impact factor: 3.573

Review 5.  Efficacy of topical non-steroidal immunomodulators in the treatment of oral lichen planus: a systematic review and meta-analysis.

Authors:  Eduardo Liberato da Silva; Taiane Berguemaier de Lima; Pantelis Varvaki Rados; Fernanda Visioli
Journal:  Clin Oral Investig       Date:  2021-08-03       Impact factor: 3.573

6.  Topical tacrolimus with custom trays in the treatment of severe oral chronic graft-versus-host disease refractory to a potent topical steroid therapy: a case report.

Authors:  Ronald S Brown; Dean Edwards; Tracey Walsh-Chocolaad; Richard W Childs
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol       Date:  2012-10-24

Review 7.  Black pepper and its bioactive constituent piperine: promising therapeutic strategies for oral lichen planus.

Authors:  Jing-Ya Yang; Jing Zhang; Gang Zhou
Journal:  Inflammopharmacology       Date:  2018-10-20       Impact factor: 4.473

8.  In vitro culture system for keratinocytes obtained from oral lichen planus lesions.

Authors:  Hong-Ying Sun; Guo-Min Zhou; Qun Wang; Xue-Cai Lin; Bin Xu
Journal:  Clin Oral Investig       Date:  2013-08-15       Impact factor: 3.573

9.  A retrospective clinicopathological study on oral lichen planus and malignant transformation: analysis of 518 cases.

Authors:  Zheng-Yu Shen; Wei Liu; Lai-Kuan Zhu; Jin-Qiu Feng; Guo-Yao Tang; Zeng-Tong Zhou
Journal:  Med Oral Patol Oral Cir Bucal       Date:  2012-11-01

10.  Epigenetic Modifications and Accumulation of DNA Double-Strand Breaks in Oral Lichen Planus Lesions Presenting Poor Response to Therapy.

Authors:  Caroline S Dillenburg; Marco A T Martins; Luciana O Almeida; Luise Meurer; Cristiane H Squarize; Manoela D Martins; Rogerio M Castilho
Journal:  Medicine (Baltimore)       Date:  2015-07       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.